The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic;
however, long-term benefit is limited to a subset of patients for select cancer indications. The …

The success of immunotherapy approaches, such as immune checkpoint blockade and
cellular immunotherapy with genetically modified lymphocytes, has firmly embedded the …

Regulatory T cells (Treg) are conventionally viewed as suppressors of endogenous and
therapy-induced antitumor immunity; however, their role in modulating responses to immune …

Background Tumor-associated tertiary lymphoid structures (TLSs) are functional immune-
responsive niches that are not fully understood in pancreatic ductal adenocarcinoma …

Although co-stimulation of T cells with agonist antibodies targeting 4-1BB (CD137) improves
antitumor immune responses in preclinical studies, clinical success has been limited by on …

Tertiary lymphoid structures (TLS) are clusters of immune cells that resemble and function
similarly to secondary lymphoid organs (SLOs). While TLS is generally associated with an …

The use of immune checkpoint inhibitors (ICIs) has become mainstream in the treatment of
non-small cell lung cancer (NSCLC). The idea of harnessing the immune system to fight …

Introduction Tissue biomarkers that aid in identifying cutaneous melanoma (CM) patients
who will benefit from adjuvant immunotherapy are of crucial interest. Metastatic tumor …

Tertiary lymphoid structure (TLS) is an ectopic lymphocyte aggregate formed in peripheral
non-lymphoid tissues, including inflamed or cancerous tissue. Tumor-associated TLS serves …